Financials

This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQANIK
Beta0.76
Shares Outstanding14.8M
Average Volume (10 days)46.6K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($1.64)
Sales (TTM)$10.52
Book Value (MRQ)$14.29
Cash Flow (TTM)($0.12)
Cash (MRQ)$7.20

Analyst Views

Current Mean RecommendationBuy
Strong Buy1
 
Buy0
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Anne Nunes
SVP, Chief Operations Officer
26,442
Acquire
Mar 15, 2024
Anne Nunes
SVP, Chief Operations Officer
10,912
Acquire
Mar 15, 2024
Levitz Michael
EVP, CFO, Treasurer
21,329
Acquire
Mar 15, 2024
Colleran David
EVP, General Counsel, Corp Sec
46,875
Acquire
Mar 15, 2024
Levitz Michael
EVP, CFO, Treasurer
51,682
Acquire
Mar 15, 2024

Recent SEC Filings

10-K/A
10-K/A
Apr 26, 2024
SC 13G/A
Amended >= 5% Acquisition
Apr 5, 2024
4
Insider Buy/Sell
Mar 19, 2024
4
Insider Buy/Sell
Mar 19, 2024
4
Insider Buy/Sell
Mar 19, 2024
Currency in USD.
Quote data delayed by at least 15 minutes.
Earnings and Analyst data provided by Zacks.
Insiders data provided by Morningstar.
To Top